Free Trial
→ This free guide explains options the way they should be taught (From Base Camp Trading) (Ad)tc pixel
NASDAQ:DYN

Dyne Therapeutics Q3 2026 Earnings Date & Estimates

Dyne Therapeutics logo
$16.64 +0.27 (+1.65%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$16.53 -0.11 (-0.67%)
As of 10/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyne Therapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for October 29, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Dyne Therapeutics in Q3 2026

Dyne Therapeutics is expected to post earnings of -$0.9122 per share. In the same quarter a year earlier Dyne Therapeutics reported -$0.76 per share. Dyne Therapeutics last reported on July 29, 2026, posting -$1.08 per share and missing the -$0.7488 consensus estimate. Dyne Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.9122
Prior-Year EPS
-$0.76

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.08 (Missed by -$0.3312)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Dyne Therapeutics Q3 2026 Earnings FAQ

Dyne Therapeutics (NASDAQ:DYN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Dyne Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Dyne Therapeutics to post earnings of -$0.9122 per share for Q3 2026.

Dyne Therapeutics Earnings Headlines

Dyne Therapeutics (NASDAQ:DYN) Stock: Insider Brian Posner Purchases 2,500 Shares
October 8 at 5:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099149
Why Dyne Therapeutics (DYN) Is Back In The Spotlight
October 7 at 9:07 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-dyne-therapeutics-dyn-back-141213797.html
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
 |  Stansberry Research (Ad)
FY2028 Earnings Forecast for DYN Issued By HC Wainwright
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083660
Chardan Capital Reaffirms "Buy" Rating for Dyne Therapeutics (NASDAQ:DYN)
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077013
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)
October 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/DYN/pressreleases/4904368/analysts-offer-insights-on-healthcare-companies-medios-ag-othermedof-and-dyne-therapeutics-dyn/
See More Dyne Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email.

About Dyne Therapeutics

Dyne Therapeutics (NASDAQ:DYN) is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping. The company has also pursued additional programs for rare muscle diseases, including Pompe disease. These candidates remain subject to clinical testing and regulatory review.

Founded in 2018 and headquartered in Waltham, Massachusetts, Dyne conducts research and clinical-development activities in the United States and through international trial networks. The company has been led by Chief Executive Officer John Cox, who joined Dyne after serving in senior leadership roles in the biotechnology industry. Dyne’s common stock trades on the Nasdaq under the symbol DYN.

View Dyne Therapeutics Profile
Earnings Tools